Trial Outcomes & Findings for Maimonides Minocycline in Stroke Study (NCT NCT06107725)

NCT ID: NCT06107725

Last Updated: 2025-12-17

Results Overview

Mortality rates during hospitalization and at 30 days

• Recruitment status: TERMINATED
• Study phase: PHASE2/PHASE3
• Target enrollment: 2 participants
• Primary outcome timeframe: 30 days
• Results posted on: 2025-12-17

Participant Flow

Participant milestones

Measure	Standard Stroke Care Without Minocycline 560 Patients will receive standard stroke care.	Standard Stroke Care With Minocycline 560 patients in the Minocycline arm will receive Minocycline 200 mg every 24 hours for five days with standard stroke care Minocycline: Minocycline 200 mg every 24 hours for five days to be initiated within 24hr of stroke onset.
Overall Study STARTED	0	2
Overall Study COMPLETED	0	0
Overall Study NOT COMPLETED	0	2

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Measure	Standard Stroke Care Without Minocycline 560 Patients will receive standard stroke care.	Standard Stroke Care With Minocycline n=2 Participants 560 patients in the Minocycline arm will receive Minocycline 200 mg every 24 hours for five days with standard stroke care Minocycline: Minocycline 200 mg every 24 hours for five days to be initiated within 24hr of stroke onset.	Total n=2 Participants Total of all reporting groups
Age, Categorical >=65 years	0 Participants	2 Participants n=2 Participants	2 Participants n=2 Participants
Sex: Female, Male Female	0 Participants	0 Participants n=2 Participants	0 Participants n=2 Participants
Age, Categorical <=18 years	0 Participants	0 Participants n=2 Participants	0 Participants n=2 Participants
Age, Categorical Between 18 and 65 years	0 Participants	0 Participants n=2 Participants	0 Participants n=2 Participants
Sex: Female, Male Male	0 Participants	2 Participants n=2 Participants	2 Participants n=2 Participants
Race and Ethnicity Not Collected	—	—	0 Participants Race and Ethnicity were not collected from any participant.
Region of Enrollment United States	—	2 participants n=2 Participants	2 participants n=2 Participants

PRIMARY outcome

Timeframe: 30 days

Population: The study was terminated after 2 patients were enrolled in the study. No patients were enrolled in the without Minocycline group.

Mortality rates during hospitalization and at 30 days

Outcome measures

Measure	Standard Stroke Care Without Minocycline 560 Patients will receive standard stroke care.	Standard Stroke Care With Minocycline n=2 Participants 560 patients in the Minocycline arm will receive Minocycline 200 mg every 24 hours for five days with standard stroke care Minocycline: Minocycline 200 mg every 24 hours for five days to be initiated within 24hr of stroke onset.
In-hospital and 30-day Mortality	0 Participants	0 Participants

Adverse Events

Standard Stroke Care Without Minocycline

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Standard Stroke Care With Minocycline

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. QingL Tony Wang

Maimonides Medical Center

Phone: 718.283.7670

Email: qwang@maimo.org

Results disclosure agreements

• Principal investigator is a sponsor employee
• Publication restrictions are in place